Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Last reviewed: June 12, 2026 Last updated: June 12, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Interestingly, studies examining placental passage of exenatide and liraglutide in human cases suggest minimal to no fetal exposure shortly after administration, indicating that maternal metabolic effects, rather than direct fetal exposure, may contribute to adverse outcomes
doi: 10.1210/en.2007-1292 Summary Keywords GLP-1, DPP-4, fracture, diabetes, bone, osteoporosis, antidiabetic, glucose-lowering drugs Citation Al-Mashhadi ZK, Viggers R, Fuglsang-Nielsen R, Vestergaard P, Gregersen S and Starup-Linde J (2022) The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
Originally developed to manage type 2 diabetes, GLP-1s have gained recognition for their efficacy in promoting weight loss by mimicking the actions of the glucagon-like peptide-1 hormone, which regulates appetite and insulin secretion
And then the media puts filters on it to make them look even more sickly
Receptor activation triggers a PLC-IP3-Ca2+ cascade leading to rapid pulsatile release of GH stored in secretion granules
